MYPHARMA: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
MYPHARMA
Largest movements
- Receivables within one year +€301
up €301 (+80.6%), from €374 to €675
- Cash -€30
down €30 (-12.6%), from €238 to €208
mainly Net result for the year (-€2,410) and Receivables within one year (-€301)
- Other debts +€2,699
up €2,699 (+67.6%), from €3,993 to €6,692
- Profit (loss) carried forward -€2,410
down €2,410 (-54.4%), from -€4,429 to -€6,839
- Trade debts -€17
down €17 (-36.4%), from €47 to €30
- Staff costs +€400
new in 2025: €400
- Gross operating margin -€322
down €322 (-20.5%), from -€1,567 to -€1,889
- Financial charges +€30
up €30 (+100.0%), from €30 to €60
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €612 | €883 | +€271 | +44.3% |
| Current assets | 29/58 | €612 | €883 | +€271 | +44.3% |
| Amounts receivable within one year | 40/41 | €374 | €675 | +€301 | +80.6% |
| Other amounts receivable | 41 | €374 | €675 | +€301 | +80.6% |
| Cash at bank and in hand | 54/58 | €238 | €208 | -€30 | -12.6% |
| Total equity and liabilities | 10/49 | €612 | €883 | +€271 | +44.3% |
| Equity | 10/15 | -€3,429 | -€5,839 | -€2,410 | -70.3% |
| Contributions | 10/11 | €1,000 | €1,000 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€4,429 | -€6,839 | -€2,410 | -54.4% |
| Amounts payable | 17/49 | €4,041 | €6,722 | +€2,682 | +66.4% |
| Amounts payable within one year | 42/48 | €4,041 | €6,722 | +€2,682 | +66.4% |
| Trade debts | 44 | €47 | €30 | -€17 | -36.4% |
| Suppliers | 440/4 | €47 | €30 | -€17 | -36.4% |
| Other amounts payable | 47/48 | €3,993 | €6,692 | +€2,699 | +67.6% |
| Remuneration, social security and pensions | 62 | - | €400 | +€400 | |
| Other operating charges | 640/8 | €62 | €62 | = | 0.0% |
| Gross operating margin | 9900 | -€1,567 | -€1,889 | -€322 | -20.5% |
| Operating profit (loss) | 9901 | -€1,629 | -€2,350 | -€722 | -44.3% |
| Financial charges | 65/66B | €30 | €60 | +€30 | +100.0% |
| Recurring financial charges | 65 | €30 | €60 | +€30 | +100.0% |
| Profit (loss) for the period before taxes | 9903 | -€1,659 | -€2,410 | -€752 | -45.3% |
| Profit (loss) for the period | 9904 | -€1,659 | -€2,410 | -€752 | -45.3% |
| Profit (loss) for the period to be appropriated | 9905 | -€1,659 | -€2,410 | -€752 | -45.3% |
Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 6 October 2026 via checked.be.